cystic fibrosis transmembrane conductance regulator


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to cystic fibrosis transmembrane conductance regulator: CFTR

cystic fibrosis transmembrane conductance regulator

[¦sis·tik fī¦brō·səs tranz¦mem‚brān kən′dək·təns ‚reg·yə‚lād·ər]
(cell and molecular biology)
A specialized chloride channel that is regulated by cyclic adenosine monophosphate; its disruption has been implicated in cystic fibrosis.
References in periodicals archive ?
A nonsense mutation (R1158X) and a splicing mutation (3849+4A[right arrow]G) in exon 19 of the cystic fibrosis transmembrane conductance regulator gene.
Vertex is currently conducting the ENDEAVOR Phase 3 registration program of VX-770, an investigational Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiator compound for the treatment of CF.
The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-activated chloride ion (Cl-) channel expressed in various epithelial cells throughout the body, and is a pharmacological target for both activators and inhibitors.
Patients with CF lack the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chloride ion channel that maintains proper hydration of epithelial cells in the lungs, pancreas, and liver.
OneWorld Health and the Novartis Institutes for BioMedical Research will join forces to discover drugs to treat infectious diarrhea via inhibition of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) chloride channel.
These studies show that treatment with PTC124 results in statistically significant improvements in a measure of the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
At both the 150 mg and 250 mg doses, significant improvements in lung function, as measured by an increase in FEV1, and significant improvements in the function of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, as measured by changes from baseline in sweat chloride levels and changes in nasal potential difference (NPD), were observed.
Nasdaq and SWX: BMRN) announced today that it has licensed from the University of California, San Francisco (UCSF) intellectual property covering compounds demonstrated to improve cystic fibrosis transmembrane conductance regulator (CFTR) protein functionality.
The milestone payment is part of a research, development and commercialization agreement between EPIX and CFFT that focuses on discovering potential drug therapies targeting the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel.
The expanded agreement follows EPIX's successful development of a validated, virtual 3-D molecule of the full length Cystic Fibrosis Transmembrane conductance Regulator (CFTR), announced in January 2008.
Full browser ?